Alamar Biosciences, Inc. (ALMR) Stock Forecast
ALMR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.40 / 5 from 5 analysts
- Price target
- $35.40 average of analyst targets
- Upside to target
- +40.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.22
- 52-week range
- $17.00 – $38.13
ALMR analyst ratings
5 analystsNumber of analysts at each rating.
ALMR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALMR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.26 | −$0.10 | — | — | 4 |
| Current fiscal year (2026) | −$1.10 | −$1.31 | −$0.86 | — | — | 4 |
| Next fiscal year (2027) | −$0.45 | −$0.90 | −$0.12 | −$1.10 | +59.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALMR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $30.2M | $30.0M | $30.4M | — | 5 |
| Current fiscal year (2026) | $118.6M | $117.8M | $119.4M | — | 5 |
| Next fiscal year (2027) | $165.7M | $157.4M | $172.1M | +39.8% | 5 |
ALMR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALMR revenue: reported and forecast
ALMR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.20 | −$0.20 | −$0.20 | −$0.19 | −10.6% | 2 up · 0 down |
| Current fiscal year (2026) | −$1.46 | −$1.16 | −$1.16 | −$1.16 | −$1.10 | −24.4% | 4 up · 0 down |
| Next fiscal year (2027) | −$0.70 | −$0.54 | −$0.54 | −$0.54 | −$0.45 | −35.8% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALMR earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; ALMR beat in 1 of 1.
What analysts expect from ALMR
5 analysts cover Alamar Biosciences; their consensus rating is buy (4.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.40, 40.0% above the latest close of $25.28. Analysts expect earnings of −$1.10 per share for 2026. For 2027 the average estimate is −$0.45 per share on revenue of $165.7 million. Alamar Biosciences beat the EPS estimate in 1 of the last 1 quarters.
Related: ALMR income statement, ALMR key metrics, ALMR chart. See the ALMR stock overview for the latest quote and news.
ALMR forecast FAQ
What is Alamar Biosciences's price target?
The average analyst price target for Alamar Biosciences is $35.40, 40.0% above the latest close of $25.28.
Is Alamar Biosciences a buy, hold or sell?
Of 5 analysts covering Alamar Biosciences, 3 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Alamar Biosciences's EPS forecast?
Analysts forecast −$1.10 per share for 2026 (range −$1.31 to −$0.86); for 2027 the estimate is −$0.45.
What is Alamar Biosciences's revenue forecast?
The average revenue estimate for 2026 is $118.6 million; for 2027 it is $165.7 million.
When does Alamar Biosciences report earnings?
Alamar Biosciences is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $-0.22.
Does Alamar Biosciences usually beat earnings estimates?
Alamar Biosciences reported EPS at or above the analyst estimate in 1 of the last 1 quarters.